Navigation Links
Patient Air Transfer System Manufacturer Announces New Variable Flow Air Supply
Date:10/28/2010

BETHLEHEM, Pa., Oct. 28 /PRNewswire/ -- HoverTech International, Inc. (www.hovermatt.com), the leading manufacturer of lateral patient air transfer systems today announced the introduction of their new Model HTAIR® 1200 Air Supply to be used in conjunction with the HoverMatt® Air Transfer System for safe patient handling. The HoverMatt® Air Transfer System has been used extensively to assist caregivers in the lateral transfer and repositioning of patients anywhere in the hospital. When used, this system has been proven to dramatically reduce back injuries to staff caused by lateral patient transfers.

After the patient is placed on the HoverMatt® transfer mattress, low pressure air from the air supply is used to inflate the mattress and, at the same time, escape from small holes on the underside of the transfer mattress. The escaping air acts as a lubricant to reduce friction which facilitates effortless transfers. The HoverMatt® Air Transfer System is available in multiple styles and sizes to accommodate any patient weight, and is ideally suited for the transfer of bariatric patients.

The new Model HTAIR® 1200 Air Supply has unique air flow control features which, until now, have never been available for air transfer systems. It offers a choice of two continuous air flow rates based on the size of the transfer mattress being used. In addition, it offers four adjustable air flow rate/pressure settings, which allows for easier, more controlled inflation of smaller positioning devices.

"This unique variable air control feature has never before been available on patient transfer system air supplies," said Dave Davis, the company President and CEO. "It is just another user-friendly advancement in a long line of innovations that continue to set HoverTech® apart from the competition."

The new Model HTAIR® 1200 is a single unit that can cover all applications. It is designed to replace both the Models AIR200G and AIR400G air supplies, which have been used up to now. It is UL Classified to conform to Standard 60601-1. For more information go to: http://www.hovermatt.com/airSupply.

About HoverTech International, Inc.:

Based in Bethlehem, PA, HoverTech is a leader in providing the healthcare industry with easier patient transfer and repositioning, resulting in a safer environment for both the caregiver and the patient. Besides the HoverMatt® products, HoverTech offers a complete line of patient transfer chairs and lifts, and the unique HoverJack® for air-inflated vertical patient lifting.

  • Image 72dpi: Send2PressNewswire.com/image/10-1027-hovermt_72dpi.jpg
  • Image Caption: HoverTech's New HTAIR 1200 Variable Flow Air Supply.

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R). http://www.Send2Press.com


'/>"/>
SOURCE HoverTech International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... , March 30, 2017  Akcea Therapeutics, a subsidiary ... initiation of a Phase 2b dose-ranging study of AKCEA-APO(a)-L ... disease. The goal of the study is to determine ... Rx in a planned Phase 3 cardiovascular outcome ... of Akcea,s strategic collaboration with Novartis to develop and ...
(Date:3/30/2017)... DUBLIN , Mar 30, 2017 ... "Hemodialysis And Peritoneal Dialysis Market Size & Forecast, By Type ... (Home-based, Hospital-based), And Trend Analysis From 2014 To 2025" ... ... market is expected to reach USD 108.5 billion by 2025. ...
(Date:3/29/2017)... Research and Markets has announced the ... Forecast By Type (Insource IONM, Outsource IONM), By Region And ... offering. ... The global Intraoperative Neuromonitoring (IONM) market is expected to ... is anticipated to witness significant growth in the forecast period, ...
Breaking Medicine Technology:
(Date:3/30/2017)... DC (PRWEB) , ... March 30, 2017 , ... ... and organizations submitted a letter to President Trump expressing their support for an ... medical doctors, two Ph.D. scientists and one medical journalist, will hold a press ...
(Date:3/29/2017)... ... March 29, 2017 , ... In the United States alone, up ... year develop other types of metastatic brain tumors(3). Though most meningiomas are benign, metastatic ... focus on finding more effective treatment options, the San Diego Gamma Knife Center ...
(Date:3/29/2017)... ... 2017 , ... Grass pollen is the main cause of hay fever in the United States, ... grass pollen runs from May to July each year; with the worst time for sufferers ... allergen barrier balms ( http://www.haymax.us ) provide an effective defense against grass pollen; they are ...
(Date:3/29/2017)... FL (PRWEB) , ... March 30, 2017 , ... Sublime ... the "Spice of Life" or "Wonder Spice", it has been used for thousands of ... in the East," says Heshelow, author of " Turmeric: How to Use it For ...
(Date:3/29/2017)... ... March 29, 2017 , ... AngioGenesis Labs ... store in Mississippi. AngioGenesis Labs, makers of HeartBoost, BrainBest and BeautyBest, achieved these ... Ingredients in HeartBoost, an over the counter heart healthy drink, can reduce Arterial ...
Breaking Medicine News(10 mins):